One of the most urgent challenges facing the American healthcare system is the complex and multifaceted issue of drug pricing. Like addressing a chronic disease, where treatment must go beyond alleviating symptoms to targeting the underlying cause, drug pricing reform requires a deep dive into the structural factors influencing the costs that burden patients.
Officials in Washington, or those hoping to get there, often say price controls will make drugs cheaper. But the high development costs, low success rates, and limited patent life that characterize the pharmaceutical industry are at the heart of today’s pricing crisis. Addressing these core issues is essential for any meaningful, long-term benefit for both patients and drug developers.
With the presidential election rapidly approaching, both candidates should be expanding their approach.
CLICK HERE to read Lamassu Biotech CEO Dr. Gabi Hanna’s column in RealClear Health.